The Delicate Dance: When Phase-Appropriate Decisions Carry More Risk
In early drug development, speed matters. But decisions made to reach the next milestone can have consequences that extend far beyond the current phase. Choices around the route of synthesis, raw materials, manufacturing operations and analytical strategy can influence scalability, specifications, timelines and costs as a program advances.
In The Delicate Dance: When Phase-Appropriate Decisions Carry More Risk, Swaroop Mathen, Senior Director, Chemical Development at Cambrex High Point, explores how emerging pharmaceutical companies can balance immediate development priorities with the needs of later-stage manufacturing.
Download the article to learn:
- Which early process decisions have the greatest potential to affect later development and scale-up.
- Why process and analytical development should evolve together to avoid disruptive and costly consequences.
- How one early-phase program overcame purification and scale-up challenges created by decisions made for toxicology studies.
- When CDMO expertise can have the greatest impact on process development and manufacturing strategy.